MTI 101Alternative Names: MTI-101
Latest Information Update: 28 Mar 2016
At a glance
- Originator Modulation Therapeutics
- Class Peptidomimetics; Small molecules
- Mechanism of Action CD44 antigen inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Multiple myeloma
Most Recent Events
- 28 Mar 2016 Preclinical trials in Multiple myeloma in USA (unspecified route) prior to March 2016 (Modulation Therapeutics website, March 2016)